Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …

Background Sinonasal neoplasms, whether benign and malignant, pose a significant
challenge to clinicians and represent a model area for multidisciplinary collaboration in …

Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …

PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma.
Here we define the epidemiological characteristics of SMM in the general population in …

Tumor recognition by T cells is essential for antitumor immunity. A comprehensive
characterization of T cell diversity may be key to understanding the success of …

A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become
available, extending progression-free and overall survival for patients in meaningful ways …

Survival in multiple myeloma has improved greatly during the past 2 decades, but this
change has primarily benefited patients who have standard-risk disease. Patients with high …

Multiple myeloma is an incurable malignancy of clonal plasma cells. Various diagnostic
methods are used in parallel to accurately determine stage and severity of the disease …